About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
GWPH - GW Pharmaceuticals P...| Previous Close | $126.53 | Open | $126.26 |
| Volume | 349.6K | Market Cap | 3.928B |
| Yield | Last Dividend |
| GW Pharma Makes Big Regulatory Step for ... | 06/24/20 |
| No summary available. | |
| UK Relaxes Rules On GWPH Cannabis Drug E... | 06/24/20 |
| Cannabis stock GW Pharma (GWPH) has announced that the UK Home Office has lowered its classification of Epidyolex (cannabidiol). This change will take... | |
| 'Dr Pot' stashes away a cannabis fortune... | 06/20/20 |
| Dr Geoffrey Guy (pictured), who earned the nickname after founding Cambridge-based GW Pharmaceuticals in 1998, made ??5.8million in 2019 as the compan... | |
| GW Pharmaceuticals (GWPH): Investments i... | 05/12/20 |
| GW Pharmaceuticals plc (NASDAQ: GWPH) has seen its stock gain over 17% in the past one month. The company delivered topline growth of over 200% in the... | |
| GW Pharma Pops 9% After-Hours As Epidiol... | 05/12/20 |
| Cannabinoid prescription medicines stock GW Pharmaceuticals (GWPH) has reported particularly strong first quarter earnings results, with US sales of E... | |
| GW Pharmaceuticals sells more of CBD-der... | 05/11/20 |
| GW Pharmaceuticals PLC undefined shares rose 2.6% in the extended session Monday after the U.K.-based company sold much more of its cannabis derived e... | |
| GW Pharmaceuticals plc Reports First Qua... | 05/11/20 |
| - Total revenue of $120.6 million - - Total Epidiolex?? net product sales of $116.1 million - - Conference call today at 4:30 p.m. EDT ??? LONDON and?... | |
| insurance market UAE, United Arab Emirat... | 04/29/20 |
| UAE Online Insurance Industry, Motor Insurance Declining Premium UAE, Life Insurance GWP Online UAE, Individual Life GWP Online UAE, Online Brokers in... | |
| The Week In Cannabis: Charlotte Figi's P... | 04/12/20 |
| A shortened week came with a no shortage of news for the cannabis community and industry. We must start with a deeply sad event: the passing of 13-yea... | |
| DEA Deschedules Expidiolex; GW Pharma's ... | 04/07/20 |
| GW Pharmaceuticals plc (NASDAQ: GWPH ) confirmed Monday it has obtained a notice from the Drug Enforcement Administration certifying that its Epidiole... | |
| GW Pharma News: GWPH Stock Jumps 6% on E... | 04/06/20 |
| GW Pharma (GWPH) news for Monday concerning the descheduling of Epidiolex as a Schedule V drug by the DEA has GWPH stock rising. | |
| The Week In Cannabis: Stocks Back In The... | 04/05/20 |
| After two strong weeks, marijuana stocks went negative again, with all major ETFs posting significant losses. Over the last five trading days: The ETF... | |
| FDA Grants GW Pharmaceuticals Priority R... | 04/01/20 |
| A new drug from GW Pharmaceuticals plc (NASDAQ: GWPH ) targeting a cause of genetic epilepsy has received Priority Review status from the U.S. Food an... | |
| Meet the top 9 startups raising millions... | 03/16/20 |
| Investment in psychedelics has ramped up in recent years and companies say that interest from traditional biotech and pharma investors has picked up a... | |
| GW Pharma Submits CBD Seizure Treatment ... | 03/13/20 |
| GW Pharmaceuticals plc (NASDAQ: GWPH ) said Friday it has submitted a Type II Variation Application to the European Medicines Agency, applying for aut... | |
| GW Pharma files application in Europe fo... | 03/13/20 |
| GW Pharmaceuticals (NASDAQ:GWPH) has filed a supplemental marketing application in Europe seeking approval to use Epidiolex (cannabidiol) to treat sei... | |
| GW Pharma submits Type II variation appl... | 03/13/20 |
| GW Pharmaceuticals (NASDAQ:GWPH) submits Type II Variation Application to the European Medicines Agency (EMA) seeking approval of EPIDYOLEX, (cannabid... | |
| Goldman likes GW Pharma in premarket ana... | 03/06/20 |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $69 (55% upside) price target at Citigroup. Alector (NASDAQ:ALEC) initiated with Bu... | |
| GW Pharma (GWPH) offers irresistible ups... | 03/05/20 |
| For GW Pharmaceuticals (NASDAQ: GWPH), the main growth strategy for the current fiscal year is to expand its product pipeline beyond Epidiolex, the hi... | |
| GW Pharma Obtains Exclusive UK Commercia... | 03/02/20 |
| GW Pharmaceuticals plc (NASDAQ: GWPH ) said Monday it will obtain exclusive rights for the commercialization of Sativex in the U.K. from Bayer AG (OTC... | |
| The Week In Cannabis: A Bunch Of Earning... | 03/02/20 |
| In another big week for cannabis, the Benzinga Cannabis Capital Conference hit Miami, with more than 1,000 attendees and an impressive lineup of speak... | |
| GW Pharma's Epidiolex Label Expansion, E... | 02/26/20 |
| GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) shares are retreating following the release of fourth-quarter results. GW Pharmaceuticals reported quarter... | |
| Oppenheimer defends GW Pharmaceuticals | 02/26/20 |
| Oppenheimer says it continues to view GW Pharmaceuticals favorably (GWPH -6.3%) even after yesterday's profit miss. "Following a year of solid commerc... | |
| The Daily Biotech Pulse: Menlo Flunks Mi... | 02/26/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. ??? | |
| GW Pharmaceuticals narrows loss in Q4, r... | 02/25/20 |
| GW Pharmaceuticals (NASDAQ:GWPH) Q4 net loss of $24.9M, or 7 cents per share, narrows from net loss of $71.9M, or 20 cents per share, in the year-ago ... | |
| GW Pharmaceuticals EPS misses by $0.03, ... | 02/25/20 |
| GW Pharmaceuticals (NASDAQ:GWPH): Q4 GAAP EPS of -$0.07 misses by $0.03. Revenue of $109.1M beats by $4.78M. Press Release | |
| GW Pharmaceuticals plc Reports Fourth Qu... | 02/25/20 |
| - Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year - - Total Epidiolex?? net product sales of $104.5 millio... | |
| Strong Buy rating | 06/01/20 |
| Oppenheimer maintains Outperform rating and lowers Price Target from $173.00 to $166.00 | |
| Strong Buy rating | 05/14/20 |
| Cantor Fitzgerald maintains Overweight rating and raises Price Target from $120.00 to $154.00 | |
| Date | 2020-05-11 (AMC) | Est. (EPS/Rev.) | ($0.85)/ 108.36M |
| Actual (EPS/Rev.) | $-0.02/ $120.63 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| High Growth Stocks- Long only | Srini Donapati | 66.00 % | Follow |
| Biotech picks | mr jackson | 50.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
